“A NOVEL RNA INTERFERENCE THERAPY TO REDUCE CARDIOVASCULAR RISK BY LOWERING LIPOPROTEIN(A) LEVELS USING THE LEPODISIRAN AGENT”, jmsi, vol. 5, no. 03, pp. 1550–1553, Mar. 2026, doi: 10.55640/.